BioCentury | Jan 12, 2021

Sanofi joins the myeloid checkpoint movement with Biond deal

Sanofi is staking claims in next-generation checkpoints through a new deal with Israeli biotech Biond around myeloid checkpoint target ILT2.  The deal with Biond Biologics Ltd., which gives the biotech $125 million up front and...
BioCentury | Jan 6, 2021

Jan. 5 Quick Takes: Myriad restructuring; plus ViGeneron-Biogen, Rhythm, Sosei and more

...labs. In point-of-care settings, the test detects antigen-specific IgM after seven days of symptoms and IgG...
BioCentury | Dec 31, 2020

Dec. 30 Quick Takes: A first for Chi-Med; plus Orphazyme, BMS, FDA REMS, Pfizer, Astellas, Alkermes, Osmotica, Quanterix, Ampio and Novartis the Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody Test from Quanterix Corp. (NASDAQ:QTRX) to detect anti-spike IgG...
...MediTech Ltd. Osmotica Pharmaceutical Corp. U.S. Food and Drug Administration (FDA) Novartis AG Cancer Autoimmune Musculoskeletal Neuroendocrine tumors Multiple sclerosis (MS) covid19 covid-19 cov19dx chs2020 bee2021 Simoa Semi-Quantitative SARS-CoV-2 IgG...
BioCentury | Dec 22, 2020
Product Development

Dec. 21-23 COVID-19 roundup: U.S. secures 100M more doses of Pfizer-BioNTech vaccine; plus Merck, BioCryst, CureVac, NIH and Sputnik V

U.S. secures an additional 100M doses of Pfizer-BioNTech vaccinePfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) entered an agreement to supply the U.S. government with an additional 100 million doses of BNT162b2 for $1.95 billion, bringing...
BioCentury | Dec 18, 2020
Product Development

Next-generation checkpoints acting on NK and T cells: Data Byte

Following the early success of anti-TIGIT mAbs in clinical development this year, interest in next-generation checkpoints has been on the rise, and there’s reason to believe that checkpoints expressed on both T cells and NK...
BioCentury | Dec 17, 2020

GSK adds to next-generation checkpoint pipeline with Surface deal

GlaxoSmithKline’s $85 million deal with Surface Oncology caps off a big month for NK cell technologies and adds PVRIG to the growing list of NK cell checkpoint targets entering pharma pipelines. ...
BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

December has been a busy month for Alzheimer’s therapies testing new hypotheses outside of amyloid, with the latest coming Wednesday from Novo Nordisk, which said it is taking semaglutide into Phase III...
BioCentury | Dec 17, 2020

Dec. 16 Quick Takes: MacroGenics' margetuximab approved for breast cancer; plus sotorasib, Mesoblast, Cardior, Takeda, Allero

First approval for MacroGenics FDA approved Margenza margetuximab-cmkb from MacroGenics Inc. (NASDAQ:MGNX) — the company’s first approved drug — to treat metastatic HER2-positive breast cancer patients...
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
BioCentury | Nov 24, 2020
Product Development

ASH preview & long shot drug pricing rules: a BioCentury podcast

On the latest edition of the BioCentury This Week podcast, BioCentury editors discuss how emerging targets, modalities and indications are stacking up at the upcoming American Society of Hematology meeting, as well as the uncertain...
Items per page:
1 - 10 of 3789